Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Trial details
- Registry ID
- NCT03643107
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)NCT03643107 | Allarity Therapeutics | Phase 2 | Completed | 2021-10-01Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |